PNP is considered as a therapeutic target in malignant lymphoproliferative diseases as treatment with its inhibitor Forodesine (BCX-1777) induced apoptosis of chronic lymphocytic leukemia (CLL) cells [36,37]. Here, PNP is linked to B-cell chronic lymphocytic leukemia.